



Statistical Theory and Related Fields

ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/tstf20

Comment: Inference after covariate-adaptive randomisation: aspects of methodology and theory

Bingkai Wang, Ryoko Susukida, Ramin Mojtabai, Masoumeh Amin-Esmaeili & Michael Rosenblum

To cite this article: Bingkai Wang, Ryoko Susukida, Ramin Mojtabai, Masoumeh Amin-Esmaeili & Michael Rosenblum (2021) Comment: Inference after covariate-adaptive randomisation: aspects of methodology and theory, Statistical Theory and Related Fields, 5:3, 190-191, DOI: <u>10.1080/24754269.2021.1905591</u>

To link to this article: https://doi.org/10.1080/24754269.2021.1905591



Published online: 29 Mar 2021.

_	
ſ	
L	6.

Submit your article to this journal oxdot S

Article views: 24



View related articles 🗹

View Crossmark data 🗹



Comment: Inference after covariate-adaptive randomisation: aspects of methodology and theory

Bingkai Wang^a, Ryoko Susukida^b, Ramin Mojtabai^b, Masoumeh Amin-Esmaeili^{b, c} and Michael Rosenblum^a

^aDepartment of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; ^bDepartment of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; ^cIranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Tehran, Iran

ARTICLE HISTORY Received 25 March 2021; Revised 25 March 2021; Accepted 16 March 2021

We thank the editor for the opportunity to write this commentary on the paper by Jun Shao. The author's paper gives an excellent review of methods developed for statistical inference when considering covariateadaptive, randomised trial designs.

We would like to mention how the results from our paper (Wang et al., 2020) fit into those described by Jun Shao. Our paper focused on stratified permuted block randomisation (Zelen, 1974) and also biased coin randomisation (Efron, 1971), which are categorised as Type 1 randomisation schemes in the author's paper. According to a survey by Lin et al. (2015) on 224 randomised clinical trials published in leading medical journals in 2014, stratified permuted block randomization was used by 70% of trials.

Our goal is to improve precision of statistical inference by combining covariate-adaptive design and covariate adjustment, while providing robustness to model misspecification. In Section 6 of the author's paper, the same goal was discussed and a linear model of potential outcomes given covariates was considered. Our results generalise those given for linearmodel-based estimators to all M-estimators (under regularity conditions), which covers many estimators used to analyse data from randomised clinical trials. Examples of M-estimators include estimators based on logistic regression (Moore & van der Laan, 2009), inverse probability weighting (Robins et al., 1994), the doubly-robust weighted-least-squares estimator (Robins et al., 2007), the augmented inverse probability weighted estimator (Robins et al., 1994; Scharfstein et al., 1999), and targeted maximum likelihood estimators (TMLE) that converge in 1-step (van der Laan & Gruber, 2012). Our results are able to handle covariate adjustment, various outcome types, repeated measures outcomes and missing outcome data under the missing at random assumption. Using data from three completed trials of substance use disorder treatments, we estimated that the precision gained due to stratified permuted block randomisation and covariate adjustment ranged from 1% to 36%.

Taylor & Francis

Check for updates

Taylor & Francis Group

Another contribution of our paper is to prove the consistency and asymptotic normality of the Kaplan-Meier estimator under stratified randomization. Its asymptotic variance was also derived. We conjecture that this result can be generalised to cover covariate-adjusted estimators for the survival function, such as estimators by Lu and Tsiatis (2011); Zhang (2015).

Disclosure statement

No potential conflict of interest was reported by the author(s).

Notes on contributors

Mr. Bingkai Wang is a PhD student of Biostatistics at the Johns Hopkins Bloomberg School of Public Health. His research focuses on causal inference and clinical trials.

Dr. Ryoko Susukida is an assistant scientist in the Department of Mental Health at the Johns Hopkins Bloomberg School of Public Health. Her areas of research expertise include public health methodology and its rigorous application in mental and behavioral health research. Her current research includes data harmonization, integrative data analysis, and evidence synthesis in theareas of substance use disorder treatment and suicide prevention research.

Dr. Ramin Mojtabai is a professor in the Department of Mental Health at the Johns Hopkins Bloomberg School of Public Health. His research focuses on mental health services research including trends and correlates of treatment seeking for depression, other common mental and substance use disorders, barriers to accessing services including stigma, process and outcome of treatments of common mental and substance use disorders in usual care settings and pharmacoepidemiology of antidepressants and other psychiatric drugs.

Dr. Masoumeh Amin-Esmaeili is a postdoctoral fellow in the Department of Mental Health at the Johns Hopkins

Bloomberg School of Public Health. Her research interests include psychiatric epidemiology, substance use disorders, epidemiology and service research.

Dr. Michael Rosenblum is an associate professor of Biostatistics at the Johns Hopkins Bloomberg School of Public Health. His research interests include adaptive clinical trial designs, robustness to model misspecification, causal inference, and HIV/AIDS prevention and treatment.

References

- Efron, B. (1971). Forcing a sequential experiment to be balanced. *Biometrika*, 58(3), 403–417. https://doi.org/10.1093 /biomet/58.3.403
- Lin, Y., Zhu, M., & Su, Z. (2015). The pursuit of balance: an overview of covariate-adaptive randomization techniques in clinical trials. *Contemporary Clinical Trials*, 45, 21–25. https://doi.org/10.1016/j.cct.2015.07.01110th Anniversary Special Issue.
- Lu, X., & Tsiatis, A. A. (2011). Semiparametric estimation of treatment effect with time-lagged response in the presence of informative censoring. *Lifetime Data Analysis*, 17(4), 566–593. https://doi.org/10.1007/s10985-011-9199-8
- Moore, K. L., & van der Laan, M. J. (2009). Increasing power in randomized trials with right censored outcomes through covariate adjustment. *Journal of Biopharmaceutical Statistics*, *19*(6), 1099–1131. https://doi.org/10.1080/105 43400903243017PMID: 20183467.
- Robins, J. M., Rotnitzky, A., & Zhao, L. P. (1994). Estimation of regression coefficients when some regressors are not

always observed. *Journal of the American Statistical Association*, 89(427), 846–866. https://doi.org/10.1080/01621459 .1994.10476818

- Robins, J. M., Sued, M., Lei-Gomez, Q., & Rotnitzky, A. (2007). Comment: performance of double-robust estimators when inverse probability weights are highly variable. *Statistical Science*, 22(4), 544–559. https://doi.org/10.1214/ 07-STS227D
- Scharfstein, D. O., Rotnitzky, A., & Robins, J. M. (1999). Adjusting for nonignorable drop-out using semiparametric nonresponse models. *Journal of the American Statistical Association*, 94(448), 1096–1120. https://doi.org/10.1080/ 01621459.1999.10473862
- van der Laan, M. J., & Gruber, S. (2012). Targeted minimum loss based estimation of causal effects of multiple time point interventions. *The International Journal of Biostatistics*, 8(1), 9. https://doi.org/10.1515/1557-4679.1370
- Wang, B., Susukida, R., Mojtabai, R., Amin-Esmaeili, M., & Rosenblum, M. (2020). Model-robust inference for clinical trials that improve precision by stratified randomization and adjustment for additional baseline variables. arXiv: 1910.13954v3.
- Zelen, M. (1974). The randomization and stratification of patients to clinical trials. *Journal of Chronic Diseases*, 27(7), 365–375. https://doi.org/10.1016/0021-9681(74)90015-0
- Zhang, M. (2015). Robust methods to improve efficiency and reduce bias in estimating survival curves in randomized clinical trials. *Lifetime Data Analysis*, *21*(1), 119–137. https://doi.org/10.1007/s10985-014-9291-y